Today we delve into the research antibody market – exploring the top five leaders, potential challengers and any further trends we’ve noticed.
This blog serves as an update to our previous piece on top antibody suppliers and marks the end of our supplier share series. Check back on the blog for supplier share insights into cell products, proteins, biochemicals and multiplex immunoassay markets.
Our antibody data is the longest running and largest dataset at CiteAb. It now encompasses both primary and secondary antibodies, and a huge:
By analysing this dataset for supplier share information, we can understand different companies’ positioning in this market and track trends over time.
Who is the market leader?
During our last analysis for the blog, our data revealed that Cell Signaling Technology, Santa Cruz Biotechnology and Abcam were vying for top position. We found that Cell Signaling Technology pulled slightly ahead of its competitors to claim that top spot.
Fast forward to 2020, and Cell Signaling Technology and Abcam continue to vye for top spot. These two well established, successful suppliers maintain their positions as clear leaders in the research antibody market – no small feat given its very competitive nature. Santa Cruz Biotechnology’s citation share has declined since our last analysis, perhaps reflecting legal issues around its polyclonal antibody business in 2016 and the challenges of an increasingly competitive market. They have now fallen to fifth position, although this still represents a significant share of the market.
Cell Signaling Technology and Abcam together claim over 40% of the citation share in research antibodies. In 2020, Abcam narrowly pipped Cell Signaling Technology to take the top spot with a <1% lead.
Abcam’s five year business plan, which we commented on in 2019, appears to be serving them well. This plan focused on extended antibody leadership, the success of which is evidenced by this citation data for 2020, coupled with expansion into related growth markets, and a ‘long term investment perspective’.
Overall, both Cell Signalling Technology and Abcam continue to convincingly lead this market and grow their citation share. We are excited to see how these leaders drive innovation and progress in the antibody sector.
Other leaders in research antibodies
Coming in at third position is Thermo Fisher Scientific, claiming citation share north of 10%. With this impressive citation share, they have managed to overtake both MilliporeSigma and Santa Cruz Biotechnology in recent years. We have also seen Thermo Fisher Scientific add products into the top 100 antibodies of 2020 list.
MilliporeSigma maintain their significant citation share, and are the fourth most cited supplier in this market, overtaking Santa Cruz Biotechnology.
Smaller challengers continue to feature in our dataset, including BioLegend and Proteintech, who have both seen rising citation share. We have recently examined in more depth their rising citation share in cancer research. This trend is something we will revisit in our blogs in the future, with further insights.
We are excited to be offering data on the top 10 antibody suppliers for 2020 – simply sign up via the form. If you are interested in more detailed datasets on the antibody market, our ‘antibody market insights‘ package, or in the full antibody supplier market data, showing citation trends from the last decade, please do get in touch.
- Rhys and the CiteAb team
Sign up for data
Something seems to have gone wrong while loading the form.
Drop us a message and we can send you the data directly.